Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
An update on a Phase 1/2 study of belantamab mafodotin with cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma indic…
-
CLINICAL_TRIALS research · 2025-04-03Clinical Trial Update: Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients [Phase 2]
Phase 2 clinical trial evaluating the triplet regimen ixazomib plus lenalidomide plus dexamethasone in newly diagnosed multiple myeloma; sta…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma [Phase 2]
Phase 2 trial evaluating teclistamab plus autologous lymphocyte infusion for relapsed/refractory multiple myeloma. The study is currently no…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
A clinical trial update indicates a study using Telo Genomics technology to detect and profile minimal residual disease in multiple myeloma …
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating Purinostat Mesylate in combination with pomalidomide and low-dose dexamethasone in relapsed o…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-04-01Clinical Trial Update: Melflufen for Elderly Patients With Relapsed Myeloma [Phase 2]
A Phase 2 trial of Melflufen in elderly patients with relapsed multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma [Phase 2]
Phase 2 trial evaluating cyclophosphamide as graft-versus-host disease prophylaxis after allogeneic stem cell transplantation in patients wi…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
The study evaluated real-world current standards of care for relapsed/refractory multiple myeloma patients who have received at least three …
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update announcing a Phase 1/2 study of belantamab mafodotin plus venetoclax for relapsed/refractory t(11;14) multiple myeloma…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: Whole Body MRI in Oncology
This clinical trial update describes a study evaluating whole-body MRI in oncology across multiple cancer types, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Chemotherapy and G-CSF for Mobilization [Phase 2]
Phase 2 trial updating the use of chemotherapy with G-CSF for stem cell mobilization in multiple myeloma; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
An update on the treatment of relapsed/refractory multiple myeloma with pomalidomide in clinical practice following completion of the trial.
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone [Phase 2]
Phase 2 clinical trial evaluating iberdomide in combination with low-dose cyclophosphamide and dexamethasone for multiple myeloma; the study…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation [Phase 1]
A Phase 1 trial evaluating the efficacy of a generic plerixafor in autologous hematopoietic stem cell transplantation has completed.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for a generic version of Plerixafor submitted by Eugia US LLC.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for Plerixafor filed by Novadoz Pharmaceuticals LLC, related to changes to labeling and/or indic…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma [Phase 1]
Phase 1 trial evaluating a conditioning regimen including bortezomib, total marrow irradiation, fludarabine phosphate, and melphalan for don…
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 study evaluating HLX15-IV versus DARZALEX in combination with lenalidomide-dexamethasone for transplant-ineligible newly diagnosed m…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma. [EARLY_Phase 1]
A Phase 1 clinical trial to evaluate the safety and efficacy of ESO-T01 for relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma [NA]
The update notes the completion of a clinical trial studying plasma exchange for acute renal failure at the onset of multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
This clinical trial update reports the termination of a Phase 1 study evaluating the safety and tolerability of CC-92328 in participants wit…
-
CLINICAL_TRIALS trial_result · 2025-03-21Clinical Trial Update: Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) [Phase 3]
Phase 3 trial evaluating oral ixazomib as maintenance therapy after initial therapy in newly diagnosed multiple myeloma patients not treated…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
This clinical trial update notes that multiple myeloma remains a relapse-prone hematologic malignancy and highlights bispecific antibodies a…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) [NA]
A CARTIER clinical trial is evaluating cardiovascular prevention strategies in elderly cancer patients and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma [NA]
This clinical trial update indicates that the LCAR-M61SQ therapy for relapsed/refractory multiple myeloma is not yet recruiting.